Enzymatica AB Interim report Q3/2022: A broader role for ColdZyme adds potential for the future

Significant events during the quarter

Significant events after the quarter

·  To ensure the long-term financing of the business, in
September the company raised about SEK 74.7 million
before issue expenses through a rights issue. The rights
issue was fully subscribed, including 63 percent
subscribed with the support of subscription rights and 1
percent without the support of subscription rights. The
company's three largest shareholders, along with the
CEO and the Chairman of the Board, subscribed for the
remainder, 36 percent, in accordance with the guarantee commitments.

·  On October 31, the journal Respiratory Research published
a study from the Medical University of Innsbruck, Austria,
which shows that ColdZyme blocks the widespread and
highly transmissible omicron variants BA.4 and BA.5 from
adhering to and infecting human cells. According to the
research group that conducted the study, this opens the
possibility that ColdZyme can be applied in the prevention
of SARS-CoV-2 spreading. Continued clinical trials are needed
to establish the effect in vivo.

Other events during the quarter

·  The company's mouth spray was launched in Mexico and Turkey, expanding the company's market by more than 200 million consumers.

Third quarter

January-September

·  Net sales reached SEK 18.5 (15.4) million.

·  The operating result totaled SEK -12.6 (-6.0) million.

·  The operating result includes non-recurring costs of SEK 6.2 million
as an effect of renegotiation of agreements with two of the company's business partners.

·  Earnings per share, basic and diluted, were SEK -0.08 (-0.04).

·  Cash flow from operating activities totaled SEK -6.0 (-16.2) million.

·  Cash flow from financing activities totaled SEK 81.1 million, of which
SEK 69.1 refer to rights issue carried out in September.

·  Net sales reached SEK 32.3 (38.5) million.

·  The operating result totaled SEK -46.6 (-34.7) million.

·  Earnings per share, basic and diluted, were SEK -0.31 (-0.24).

·  Cash flow from operating activities totaled SEK 37.7 (-29.3) million.

·  Net cash totaled SEK 57.3 (35.7) million.